TELO - Kapitalisasi marang volume dodolan Telomir Pharmaceuticals Inc

Logo korporat perusahaan Telomir Pharma (TELO)

Telomir Pharmaceuticals relies on partnerships with clinics to develop anti-aging formulas. This P/S multiple chart visualizes the market reaction to these alliances, where determines the latest valuation metric. The absence of commercial sales leaves the company dependent on investor capital, although ambitions in cellular rejuvenation and the fight against tissue degeneration sustain high interest from the scientific community.

TELO Rasio rega marang pendapatan telomirpharma.com (04.07.2022 - 15.11.2026)

Rincian metrik lan analitis perusahaan telomirpharma.com (TELO)

- rega saham lan konsensus proyeksi valuasi:
Analisis umum perusahaan:TELO, Telomir Pharmaceuticals Inc
Produk seri Telomir Pharmaceuticals

The scale of Telomir Pharmaceuticals (TELO) business is clearly reflected in the P/S fluctuation, which links market capitalization to sales volume. This multiple measures the value of each unit of revenue, demonstrating the company's ability to pass inflationary costs onto consumers. For a drug developer, this calculation is critical, as geopolitical risks and sanctions directly impact the stability of component supplies. An increasing ratio signals investor confidence, yet creates a risk of correction should clinical trials fail.

Pesaing Telomir Pharmaceuticals

HLN (Haleon) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue Inc KVUE|Verona Pharma Corp - Rasio rega marang pendapatan|MENS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Rasio rega marang pendapatan|Perrigo Company PLC - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan alvotech.com|Multiplikator P/S Liquidia Technologies|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP: Rasio rega marang dodolan|Multiplikator P/S MNKD (MannKind Corp)|Koefisien rega marang pendapatan Amphastar (AMPH)|PCRX: Kapitalisasi marang pendapatan|SPRY - Multiplikator P/S|Theravance Biopharma, Inc. (TBPH) - Rasio rega marang pendapatan|AQST (Aquestive Therapeutics) - Rasio rega marang pendapatan|SCPH (scpharmaceuticals.com) - Multiplikator P/S|TECX: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EPRX (Eupraxia Pharmaceuticals)|Rasio kapitalisasi pasar marang pendapatan BHST|Invizyne Technologies - Multiplikator P/S|oramed.com (ORMP) - Kapitalisasi marang pendapatan|ENTX (enterabio.com) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan HYFT|ABVC (ABVC BioPharma, Inc) - Multiplikator P/S|Multiplikator P/S cumberlandpharma.com|Rasio rega marang pendapatan Quantum BioPharma (QNTM)|FibroGen (FGEN) - Multiplikator rega marang pendapatan|Multiplikator P/S RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Rasio rega marang dodolan|RLYB: Kapitalisasi marang pendapatan|lexariabioscience.com (LEXX) - Kapitalisasi marang pendapatan|Pulmatrix Inc (PULM) - Rasio rega marang pendapatan|PTHL: Kapitalisasi marang volume dodolan|APM (Aptorum Group Ltd) - Multiplikator P/S|Lyra Therapeutics Inc (LYRA) - Koefisien rega marang pendapatan|Multiplikator P/S IBO|Kapitalisasi marang volume dodolan TNFA|cbdMD, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PRFX|Altamira Therapeutics Ltd. - Multiplikator P/S|LIPO: Rasio rega marang pendapatan|OPTN: Multiplikator P/S|Rasio rega marang dodolan PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - Multiplikator P/S|PTPI (Petros Pharmaceuticals Inc) - Kapitalisasi marang volume dodolan|Multiplikator P/S QLI|SLRN - Rega marang dodolan|Multiplikator P/S TFFP (TFF Pharmaceuticals, Inc)